Jr. Schlicht et al., REEVALUATION OF A WEIGHT-BASED HEPARIN DOSING NOMOGRAM - IS INSTITUTION-SPECIFIC MODIFICATION NECESSARY, The Annals of pharmacotherapy, 31(12), 1997, pp. 1454-1459
OBJECTIVE: TO compare a heparin dosing nomogram using an initial infus
ion rate of 18 units/kg/h with physician-directed heparin prescribing
and with a modified version of the nomogram adjusted for institution-s
pecific data. METHODS: During consecutive phases of this cohort study,
patients' intravenous heparin therapies were initiated and adjusted b
y using one of the following three methods: (I) physician-directed dos
ing, (2) a body weight-based dosing nomogram with an initial infusion
rate of 18 units/kg/h, and (3) a body weight-based dosing nomogram wit
h an initial infusion rate determined by the median dose of heparin (i
n units/kg/h) required to achieve therapeutic activated partial thromb
oplastin times (aPTTs) during the first two phases. The time required
to achieve therapeutic aPTTs as well as the percentage of initial aPTT
s in the therapeutic range were compared for the three phases. RESULTS
: The heparin dosing nomogram in which the initial infusion rate was a
djusted for our individual institution resulted in a statistically sho
rter median time until aPTTs were in the therapeutic range than did ei
ther the physician-directed dosing or unmodified nomogram groups (6.1
h in the modified nomogram group, 10.5 h in the physician-directed gro
up, 21.5 h in the unmodified nomogram group; p < 0.05 for all differen
ces). Use of the institution-specific nomogram resulted in the greates
t percentage of initial aPTTs in the therapeutic range (84% in the 13
units/kg/h nomogram group vs, 47% in the physician-directed group and
18% in the 18 units/kg/h nomogram group; p < 0.05 for all differences)
, CONCLUSIONS: Use of a heparin dosing nomogram with an initial infusi
on rate of 18 units/kg/h resulted in prolongation of the time to reach
therapeutic aPTTs, By modifying the nomogram for use at an individual
institution, we reduced the time to achieve therapeutic range of aPTT
s while still reducing the likelihood of excessive anticoagulation of
patients.